

Title (en)
IL-2 MUTEINS AND USES THEREOF

Title (de)
IL-2 MUTEINE UND DEREN VERWENDUNG

Title (fr)
MUTÉINES D'IL-2 ET LEURS UTILISATIONS

Publication
EP 3720470 A4 20210915 (EN)

Application
EP 18887098 A 20181128

Priority

- US 201762595357 P 20171206
- US 201862675972 P 20180524
- US 201816109875 A 20180823
- US 201816109897 A 20180823
- US 201862721644 P 20180823
- US 2018062808 W 20181128

Abstract (en)
[origin: WO2019112854A1] Described herein are therapeutics that can modulate (e.g. increase) T-reg cell proliferation, survival, activation and/or function. In some embodiments, the modulation is selective or specific for the T-reg cells. The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same. In another aspect, the present embodiments provide compositions, e.g., pharmaceutically acceptable compositions, which include a therapeutic compound (IL-2 mutein) described herein, formulated together with a pharmaceutically acceptable carrier. Also within the scope of the invention is a kit comprising a therapeutic compound described herein.

IPC 8 full level
A61K 38/20 (2006.01); **A61K 47/68** (2017.01); **A61P 29/00** (2006.01); **A61P 37/02** (2006.01); **A61P 37/04** (2006.01); **A61P 37/06** (2006.01)

CPC (source: EP IL KR)
A61K 38/00 (2013.01 - IL); **A61K 47/65** (2017.08 - EP IL KR); **A61K 47/68** (2017.08 - EP IL KR); **A61P 29/00** (2018.01 - EP IL KR); **A61P 37/02** (2018.01 - EP IL); **A61P 37/04** (2018.01 - EP IL); **A61P 37/06** (2018.01 - EP IL); **C07K 14/55** (2013.01 - EP IL KR); **A61K 38/00** (2013.01 - EP KR); **C07K 2319/30** (2013.01 - EP IL KR)

Citation (search report)

- [E] WO 2019112852 A1 20190613 - PANDION THERAPEUTICS INC [US]
- [E] WO 2018217989 A1 20181129 - PANDION THERAPEUTICS INC [US]
- [E] WO 2020061142 A1 20200326 - PANDION THERAPEUTICS INC [US]
- See also references of WO 2019112854A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2019112854 A1 20190613; AU 2018378078 A1 20200618; AU 2018378078 B2 20240725; AU 2024216451 A1 20240926; BR 112020011343 A2 20201117; CA 3083941 A1 20190613; CN 111432831 A 20200717; CN 111432831 B 20240816; CN 118515780 A 20240820; EP 3720470 A1 20201014; EP 3720470 A4 20210915; IL 274844 A 20200730; JP 2021507690 A 20210225; JP 7250790 B2 20230403; KR 102684426 B1 20240711; KR 102687035 B1 20240722; KR 20200097275 A 20200818; KR 20240039201 A 20240326; KR 20240115352 A 20240725; MX 2020005208 A 20200820; SG 11202003965V A 20200629

DOCDB simple family (application)
US 2018062808 W 20181128; AU 2018378078 A 20181128; AU 2024216451 A 20240829; BR 112020011343 A 20181128; CA 3083941 A 20181128; CN 201880077653 A 20181128; CN 202410591221 A 20181128; EP 18887098 A 20181128; IL 27484420 A 20200521; JP 2020530653 A 20181128; KR 20207017255 A 20181128; KR 20247008135 A 20181128; KR 20247023942 A 20181128; MX 2020005208 A 20181128; SG 11202003965V A 20181128